Skip to content

Study of Titanium-Coated PEEK Cages for Degenerative Disc Disease

Prospective Follow-up Study of CeSPACE XP - Titanium Coated PEEK Cages - for the Treatment of Degenerative Cervical Disc Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03565224
Enrollment
50
Registered
2018-06-21
Start date
2018-01-10
Completion date
2018-12-31
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Vertebral Fusion, Spinal Fusion

Keywords

Cervical vertebrae, Postoperative complications, Radiography, Spinal fusion, Coating

Brief summary

Prospective Follow-up study of CeSPACE XP coated PEEK cages for the treatment of degenerative cervical disc disease

Detailed description

Anterior cervical discectomy and fusion (ACDF) has been accepted as the standard procedure for the treatment of myelopathy and radiculopathy in the cervical spine. A tricortical iliac crest bone graft is the traditional inter-body fusion material that can show perfect bony fusion and maintain the patency of the neuroforamen. However, donor site complications were reported in fusion with an iliac bone graft, such as subcutaneous hematomas, infections, and chronic wound pain. Currently, the titanium cage and polyetheretherketone (PEEK) cage are the two most common cages in clinical practice. The ideal cage should lead to a high fusion rate and prevent complications, such as subsidence and loss of correction. Even though a titanium cage can provide long-term stabilization, increase lordosis, and increase foramina height compared with the iliac bone graft, some inferior clinical outcomes appeared in clinical practice. Loss of correction is a major complication of subsidence that may eventually affect cervical spinal function after the operation. A modulus of elasticity close to cortical bone might contribute to advantages in stress distribution and load sharing, which can contribute to a lower subsidence rate and, thus, better clinical results, making PEEK cages more welcomed by surgeons. It is supposed, that in the cervical fusion procedure, a porous coating of a PEEK cage will lead to favourable results. Therefore, the present study intends to show these results, in a larger patient cohort who received such a coated cervical cage.

Interventions

None listed

Sponsors

Aesculap AG
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All consecutive patients who received a CeSPACE XP cage between August 2013 and January 2017

Exclusion criteria

* Pregnancy * Patient consent not signed

Design outcomes

Primary

MeasureTime frameDescription
Neck Disability Index (NDI) during Follow-UpOnce between 1 to 4 years postoperativeThe Neck Disability Index(NDI) is a modification of the Oswestry Low Back Pain Disability Index . It is a patient-completed, condition-specific functional status questionnaire with 10 items including pain, personal care, lifting, reading, headaches, concentration, work, driving, sleeping and recreation. The NDI has sufficient support and usefulness to retain its current status as the most commonly used self-report measure for neck pain. The NDI can be scored as a raw score or doubled and expressed as a percent. Each section is scored on a 0 to 5 rating scale, in which zero means 'No pain' and 5 means 'Worst imaginable pain'. All the points can be summed to a total score.

Secondary

MeasureTime frameDescription
Patient Satisfaction at Follow-UpOnce between 1 to 4 years postoperativePatient self-reported satisfaction measured by a four-level scale: excellent, good, not satisfied, bad
Neck Pain at Follow-UpOnce between 1 to 4 years postoperativePatient self-reported Neck Pain measured by Visual Analogue Scale (VAS). The VAS is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Arm Pain during Follow-UpOnce between 1 to 4 years postoperativePatient self-reported Arm Pain measured by Visual Analogue Scale (VAS). The VAS is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points.
Neurological Outcome at Follow-Up1 to 4 years follow-upCurrent neurological assessment at follow-up, measured by a four-level scale: no deficit, sensory deficit, motor deficit, sensory & motor deficit
Radiographic Evaluation of Mobility at Follow-UpOnce between 1 to 4 years postoperativeRadiological evaluation: Fusion criteria 1: Degree of Flexion, Degree of Extension, Mobility (Extension-Flexion)
Radiographic Evaluation of Bone Bridges at Follow-UpOnce between 1 to 4 years postoperativeRadiological evaluation: Fusion criteria 2: no bone bridges between adjacent vertebral bodies, Radiological densities visible compared to directly postop state, Bone Bridges linking adjacent vertebral bodies (anterior / posterior)
Radiographic Evaluation of Radiolucencies at Follow-UpOnce between 1 to 4 years postoperativeRadiological evaluation: Fusion criteria 3: no radiolucent line along the implant end plate (0%), mild / under 25% radiolucencies, moderate / 25-50% radiolucencies, severe / more than 50% radiolucencies
Work Status at Follow-UpOnce between 1 to 4 years postoperativecurrent profession and working level

Other

MeasureTime frameDescription
Rate of Patients with Adverse Events and Serious Adverse Events during Follow-upUp to 4 years postoperativeNumber of Patients who had potential reoperations and revisions

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026